NASDAQ:ALT

Altimmune Stock Insider Trading

Healthcare > Biotechnology

Buy ALT

*Your capital is at risk

$2.87

-0.0300 (-1.03%)

At Close: Jun 03, 2026

Altimmune Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 97.63. In total, the insiders bought 7.36M and sold 83.48K ALT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	97.63
● Buy	7.36M shares
● Sell	83.48K shares
87% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Dec 01, 2025 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 97.63. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (87% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 01, 2026 Buy	Stock Options (option to buy) A-Award	Gill John Director	Director	48 800 Value: $137.6K
May 01, 2026 Buy	Stock Options (option to buy) A-Award	Pisano Wayne Director	Director	48 800 Value: $137.6K
May 01, 2026 Buy	Stock Options (option to buy) A-Award	Jorkasky Diane Director	Director	48 800 Value: $137.6K
May 01, 2026 Buy	Stock Options (option to buy) A-Award	Lawver Teri L Director	Director	48 800 Value: $137.6K
May 01, 2026 Buy	Stock Options (option to buy) A-Award	Sohn Catherine A. Director	Director	48 800 Value: $137.6K
May 01, 2026 Buy	Stock Options (option to buy) A-Award	Schafer Klaus Director	Director	48 800 Value: $137.6K
May 01, 2026 Buy	Stock Options (option to buy) A-Award	Hodges Philip Director	Director	48 800 Value: $137.6K
May 01, 2026 Buy	Stock Options (option to buy) A-Award	Sayare Mitchel Director	Director	48 800 Value: $137.6K
Apr 06, 2026 Buy	Common Stock, par value $0.0001 P-Purchase	Gill John Director	Director	9 200 Value: $31.3K
Apr 01, 2026 Buy	Common Stock, par value $0.0001 P-Purchase	Weaver Gregory L Chief Financial Officer	C-Suite Officer	10 000 Value: $31.5K
Apr 01, 2026 Buy	Common Stock, par value $0.0001 P-Purchase	Durso Jerome Benedict President And CEO	CEO / President	15 000 Value: $47.1K
Mar 06, 2026 Buy	Common Stock, par value $0.0001 P-Purchase	Durso Jerome Benedict President And CEO	CEO / President	20 000 Value: $70.8K
Mar 06, 2026 Buy	Common Stock, par value $0.0001 P-Purchase	Weaver Gregory L Chief Financial Officer	C-Suite Officer	5 000 Value: $17.7K
Feb 26, 2026 Buy	Restricted Stock Units A-Award	Roberts M Scot Chief Scientific Officer	Officer	95 430 Value: $425.6K
Feb 26, 2026 Buy	Stock Options (option to buy) A-Award	Roberts M Scot Chief Scientific Officer	Officer	222 670 Value: $993.1K
Feb 26, 2026 Buy	Stock Options (option to buy) A-Award	Weaver Gregory L Chief Financial Officer	C-Suite Officer	259 000 Value: $1.16M
Feb 26, 2026 Buy	Restricted Stock Units A-Award	Weaver Gregory L Chief Financial Officer	C-Suite Officer	111 000 Value: $495.1K
Feb 02, 2026 Buy	Restricted Stock Units M-Exempt	Roberts M Scot Chief Scientific Officer	Officer	7 775 Value: $43.2K
Feb 02, 2026 Sell	Common Stock, par value $0.0001 F-InKind	Roberts M Scot Chief Scientific Officer	Officer	2 329 Value: $12.9K
Feb 02, 2026 Buy	Common Stock, par value $0.0001 M-Exempt	Roberts M Scot Chief Scientific Officer	Officer	7 775 Value: $43.2K
Jan 31, 2026 Buy	Common Stock, par value $0.0001 A-Award	Roberts M Scot Chief Scientific Officer	Officer	5 567 Value: $17.1K
Jan 31, 2026 Buy	Common Stock, par value $0.0001 A-Award	Jordt Raymond M Chief Business Officer	Officer	4 571 Value: $14.0K
Jan 31, 2026 Buy	Common Stock, par value $0.0001 A-Award	Garg Vipin K Director	Director	6 926 Value: $21.3K
Jan 30, 2026 Buy	Restricted Stock Units M-Exempt	Roberts M Scot Chief Scientific Officer	Officer	9 275 Value: $51.9K
Jan 30, 2026 Sell	Common Stock, par value $0.0001 F-InKind	Roberts M Scot Chief Scientific Officer	Officer	2 859 Value: $16.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ALTIMMUNE, INC.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica...

Read Full Profile Here